Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott H Dickerson

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Bioorganic & Medicinal Chemistry Letters|December 11, 2012
The discovery of potent and selective 4-aminothienopyridines as B-Raf kinase inhibitorsJun Tang, Karen E Lackey, Scott H Dickerson
Bioorganic & Medicinal Chemistry Letters|July 30, 2008
Knowledge-based design of 7-azaindoles as selective B-Raf inhibitorsJun Tang, Toshihiro Hamajima, Masato Nakano, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 2, 2005
Chemical genomic profiling to identify intracellular targets of a multiplex kinase inhibitorCharles Kung, Denise M Kenski, Scott H Dickerson, et al.
Journal of Medicinal Chemistry|September 3, 2004
N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacyFrancis X Tavares, Joyce A Boucheron, Scott H Dickerson, et al.
Bioorganic & Medicinal Chemistry Letters|April 15, 2004
Novel GSK-3 inhibitors with improved cellular activityAndrew J Peat, Dulce Garrido, Joyce A Boucheron, et al.
Molecular Cancer Therapeutics|March 6, 2012
Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutationsJames G Greger, Stephen D Eastman, Vivian Zhang, et al.
Bioorganic & Medicinal Chemistry Letters|October 10, 2008
Dual EGFR/ErbB-2 inhibitors from novel pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidinesRobert D Hubbard, Scott H Dickerson, Holly K Emerson, et al.
Bioorganic & Medicinal Chemistry Letters|April 15, 2004
Novel pyrazolopyrimidine derivatives as GSK-3 inhibitorsAndrew J Peat, Joyce A Boucheron, Scott H Dickerson, et al.
Cancer Research|September 18, 2004
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cellsEdgar R Wood, Anne T Truesdale, Octerloney B McDonald, et al.
Bioorganic & Medicinal Chemistry Letters|December 20, 2008
Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residuesSteven M Sparks, Pierette Banker, David M Bickett, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Bioorganic & Medicinal Chemistry Letters|December 11, 2012
The discovery of potent and selective 4-aminothienopyridines as B-Raf kinase inhibitorsJun Tang, Karen E Lackey, Scott H Dickerson
Bioorganic & Medicinal Chemistry Letters|July 30, 2008
Knowledge-based design of 7-azaindoles as selective B-Raf inhibitorsJun Tang, Toshihiro Hamajima, Masato Nakano, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 2, 2005
Chemical genomic profiling to identify intracellular targets of a multiplex kinase inhibitorCharles Kung, Denise M Kenski, Scott H Dickerson, et al.
Journal of Medicinal Chemistry|September 3, 2004
N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacyFrancis X Tavares, Joyce A Boucheron, Scott H Dickerson, et al.
Bioorganic & Medicinal Chemistry Letters|April 15, 2004
Novel GSK-3 inhibitors with improved cellular activityAndrew J Peat, Dulce Garrido, Joyce A Boucheron, et al.
Molecular Cancer Therapeutics|March 6, 2012
Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutationsJames G Greger, Stephen D Eastman, Vivian Zhang, et al.
Bioorganic & Medicinal Chemistry Letters|October 10, 2008
Dual EGFR/ErbB-2 inhibitors from novel pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidinesRobert D Hubbard, Scott H Dickerson, Holly K Emerson, et al.
Bioorganic & Medicinal Chemistry Letters|April 15, 2004
Novel pyrazolopyrimidine derivatives as GSK-3 inhibitorsAndrew J Peat, Joyce A Boucheron, Scott H Dickerson, et al.
Cancer Research|September 18, 2004
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cellsEdgar R Wood, Anne T Truesdale, Octerloney B McDonald, et al.
Bioorganic & Medicinal Chemistry Letters|December 20, 2008
Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residuesSteven M Sparks, Pierette Banker, David M Bickett, et al.
Pageof 2